UC Berkeley spinout explores gene-editing approach to GLP-1 based weight-loss therapy

UC Berkeley researchers have launched a startup that plans to use jumping genes to deliver GLP-1 gene therapy for obesity treatment. The approach seeks to create a long-lasting source of the hormone within patients rather than relying on repeated drug injections.

Current GLP-1 medicines can keep weight off effectively, but studies show many patients stop taking them over time. The new therapy aims to overcome this adherence problem by embedding the gene directly into cells.

If successful, the gene-editing strategy could provide a more durable solution for weight management, though the concept remains early-stage and will require further development and regulatory review.